Abstract
We evaluated the clinical value of gatifloxacin (GFLX), a new 8-methoxy quinolone antibacterial agent, in the treatment of complicated urinary tract infections associated with indwelling catheters. Forty-seven patients, 20 to 80 years old, with pyuria of at least 5WBCs/hpf and bacteriuria of at least 104CFU/mL were enrolled in the study and orally treated with GFLX at doses of 200 mg b. i. d.(200mg group) or 300 mg b. i. d.(300mg group) for 7 days. Clinical efficacy was evaluated according to the criteria of the Japanese UTI Committee. The overall clinical efficacy rate (excellent and moderate) was70.0% among the 20 patients in the 200mg group and 68.8% among the16patients in the 300mg group. The overall bacteriological eradication rate was 88.3% of 60 strains in the 200mg group and 88.9% of 36 strains in the 300mg group. The incidence of clinical adverse reactions was 7.7%(2/26 cases) in the 200mg group and 9.5%(2/21 cases) in the300mg group, and the incidence of laboratory adverse reactions was 0%(0/26 cases) in the 200mg group and 12.5%(2/16 cases) in the 300mg group. None of the adverse reactions were serious. The overall safety rating was 96.2%(25/26 cases) in the 200mg group and 88.9%(16/18 cases) in the 300 mg group. Based on the above results, we conclude that GFLX is safe and effective in the treatment of complicated urinary tract infections associated with indwelling catheters, and that 200 mg b. i. d. is a sufficient dosage of GFLX.
